July 23, 2017 2:36 PM ET

Biotechnology

Company Overview of Galera Therapeutics, Inc.

Company Overview

Galera Therapeutics, Inc., a clinical-stage biotechnology company, develops drugs targeting oxygen metabolic pathways. The company primarily focuses on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer. Its small molecule dismutase mimetics mimics the activity of the human superoxide dismutase enzymes. The company was founded in 2009 and is based in Malvern, Pennsylvania.

2 West Liberty Boulevard

Suite 110

Malvern, PA 19355

United States

Founded in 2009

Phone:

610-725-1500

Key Executives for Galera Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 60
Founder, Chief Operating Officer and Director
Chief Financial Officer
Age: 68
Chief Medical Officer
Director of Business Development
Compensation as of Fiscal Year 2017.

Galera Therapeutics, Inc. Key Developments

Galera Therapeutics, Inc. Completes Enrollment in Phase 2B Clinical Trial with Lead Compound GC4419 for Treatment of Oral Mucositis

Galera Therapeutics, Inc. announced that it has completed enrollment in its phase 2b clinical trial evaluating the efficacy, safety and tolerability of GC4419 as a treatment for reducing the incidence and duration of oral mucositis (OM) in head and neck cancer patients receiving chemoradiation therapy. GC4419 is a novel dismutase mimetic designed to prevent the damaging effects of radiation in normal tissue by rapidly converting superoxide to hydrogen peroxide. The phase 2b clinical trial is a double blind, randomized, controlled trial of 223 head and neck cancer patients treated with either 30mg or 90mg of GC4419 or placebo infusion on the days they receive their radiation treatment. The primary outcome measure is the duration of severe OM (defined as World Health Organization Grade 3 or 4) experienced by patients receiving 7 weeks of radiation therapy plus cisplatin. Secondary endpoints include incidence of severe OM.

Galera Therapeutics, Inc. Presents at Boston CEO Conference, May-30-2017 10:50 AM

Galera Therapeutics, Inc. Presents at Boston CEO Conference, May-30-2017 10:50 AM. Venue: Four Season Boston, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Robert A. Beardsley, Founder, Chief Operating Officer and Director.

Galera Therapeutics, Inc. Presents at BD Boston, Mar-09-2017 01:20 PM

Galera Therapeutics, Inc. Presents at BD Boston, Mar-09-2017 01:20 PM. Venue: The Colonnade Hotel, 120 Huntington Avenue, Boston, MA 02116, United States. Speakers: Robert A. Beardsley, Founder, Chief Operating Officer and Director.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Galera Therapeutics, Inc., please visit www.galeratx.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.